WNT4: A Drug Target / Disease Biomarker (G54361)

Target Name: WNT4

NCBI ID: G54361

WNT4

WNT4: A Drug Target / Disease Biomarker

WNT4 is a gene that has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and its potential as a drug target have made it an attractive target for researchers to investigate.

WNT4 is a transmembrane protein that is expressed in many different tissues throughout the body. Its function is not well understood, but it is known to be involved in the development and maintenance of tissues that are involved in the development of cancer. WNT4 has been shown to be involved in the regulation of cell proliferation, and it has been linked to the development of many types of cancer, including breast, ovarian, and prostate cancer.

One of the reasons for the potential drug target status of WNT4 is its involvement in the development of cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. WNT4 has been shown to be involved in the regulation of cell growth and division, which could make it an attractive target for drugs that are designed to inhibit cancer cell growth. Additionally, WNT4 has been shown to be involved in the development of stem cells, and it has been suggested that it may play a role in the regulation of stem cell development and maintenance.

Another reason for the potential drug target status of WNT4 is its involvement in neurodegenerative diseases. Neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. WNT4 has been shown to be involved in the development and maintenance of neural stem cells, which are important for the development and maintenance of the nervous system. Additionally, WNT4 has been shown to be involved in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. This suggests that WNT4 may be involved in the development and progression of neurodegenerative diseases.

In addition to its potential role in cancer and neurodegenerative diseases, WNT4 has also been suggested as a potential biomarker for these conditions. The development and progression of cancer and neurodegenerative diseases can be monitored by the presence of certain genes, including WNT4. This suggests that WNT4 may be an attractive biomarker for these conditions, and that its levels or expression may be useful for the diagnosis and prognosis of these diseases.

The potential drug target status of WNT4 is based on several different lines of evidence. Firstly, WNT4 has been shown to be involved in the regulation of cell growth and division, which are important processes that are involved in the development of cancer. Secondly, WNT4 has been shown to be involved in the development and maintenance of neural stem cells, which are important for the development and maintenance of the nervous system. Thirdly, WNT4 has been shown to be involved in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain.

The potential drug target status of WNT4 is also based on its unique expression pattern in different tissues. WNT4 is expressed in many different tissues throughout the body, including the brain, the pancreas, and the placenta. This makes it difficult to study the function of WNT4, as it is difficult to ensure that the effects of a drug will only affect the cells in the target tissue. However, the expression of WNT4 in different tissues provides some indication of its potential as a drug target.

In conclusion, the potential drug target status of WNT4 is based on several different lines of evidence. Its involvement in the regulation of cell growth and division, its involvement in the development and maintenance of neural stem cells, and its involvement in the regulation of the blood-brain barrier suggest that it may be an attractive target for drugs that are designed to inhibit cancer cell growth or promote the development of neural stem cells. Additionally, the potential biomarker status of WNT4 makes it an attractive target for drugs that are designed to diagnose and

Protein Name: Wnt Family Member 4

Functions: Ligand for members of the frizzled family of seven transmembrane receptors (Probable). Plays an important role in the embryonic development of the urogenital tract and the lung (PubMed:15317892, PubMed:16959810, PubMed:18179883, PubMed:18182450). Required for normal mesenchyme to epithelium transition during embryonic kidney development. Required for the formation of early epithelial renal vesicles during kidney development (By similarity). Required for normal formation of the Mullerian duct in females, and normal levels of oocytes in the ovaries (PubMed:15317892, PubMed:16959810, PubMed:18182450). Required for normal down-regulation of 3 beta-hydroxysteroid dehydrogenase in the ovary (PubMed:15317892, PubMed:16959810, PubMed:18182450). Required for normal lung development and for normal patterning of trachael cartilage rings (By similarity)

The "WNT4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WNT4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets